Multiplexed cancer cell line screening

PRISM rapidly screens a wide range of drugs across more than 900 human cancer cell line models using a high-throughput, multiplexed approach.

Sensitive viability screening across an extensive, diverse cell line collection

Large-scale cancer cell line screening is critical to oncology drug discovery and development to better understand how drugs work. Traditional phenotypic screening tests only one cell line at a time using a lot of resources and taking a lot of time. Generating data for a small subset of cell lines results in an incomplete understanding of your drug.

Using PRISM, we accelerate the screening process by employing a novel DNA barcode-based approach that enables simultaneous high-throughput viability analysis of over 900 cell lines from over 45 cancer subtypes. Our extensive cell line collection captures the diversity of human cancers to provide a comprehensive evaluation of oncology drug candidates.

Benefits

Data from over 900 cancer cell lines including rare & pediatric models
Multi-omic characterization of the cell lines
Ability to screen single agent, combination, and aqueous-format drugs
Leverage the biological and computational expertise of the Broad Institute

Applications

Identify and validate potential patient populations
Biomarker discovery and predictive modeling
Discover and validate drug mechanisms of action
Reveal drug toxicities

PRISM supports precision medicine development from discovery to clinical candidates

Working with PRISM

Collaborators leveraging the PRISM assay

Hundreds of collaborators are partnering with PRISM including over 30 biotech and pharmaceutical companies.

Find out how PRISM can help accelerate your research

Read about the PRISM assay

Learn about our collaborative working model and requirements for screening

See collaboration details

Reach out to our team